deferasirox Exjade
Selected indexed studies
- Deferasirox (ExJade): An FDA-Approved AIEgen Platform with Unique Photophysical Properties. (J Am Chem Soc, 2021) [PMID:33428381]
- Deferasirox alleviates DSS-induced ulcerative colitis in mice by inhibiting ferroptosis and improving intestinal microbiota. (Life Sci, 2023) [PMID:36563842]
- Deferasirox (Exjade): a new iron chelator. (Med Lett Drugs Ther, 2006) [PMID:16625144]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Deferasirox alleviates DSS-induced ulcerative colitis in mice by inhibiting ferroptosis and improving intestinal microbiota. (2023) pubmed
- Deferasirox. (2007) pubmed
- Deferasirox: pharmacokinetics and clinical experience. (2012) pubmed
- Deferasirox: A comprehensive drug profile. (2024) pubmed
- Deferasirox desensitization. (2016) pubmed
- Deferasirox (ExJade): An FDA-Approved AIEgen Platform with Unique Photophysical Properties. (2021) pubmed
- Deferasirox (Exjade): a new iron chelator. (2006) pubmed
- Combination chelation therapy. (2023) pubmed
- PMID:37933925 (2023) pubmed
- Deferasirox (Exjade) for the treatment of iron overload. (2009) pubmed